Kornimate/medical-research-clean huggingface dataset:
neurological outcomes after in-hospital cardiac arrest

Conditions: Inhospital Cardiac Arrest

Summary: little is known about the long-term neurological outcomes after in-hospital cardiac arrest (ihca). it is also not known whether withdrawal of life-sustaining measures will influence rates of survivors with poor neurological status. currently, withdrawal of care in comatose patients after cardiac arrest is strongly forbidden by law in korea. however, a new legislation on allowing withdrawal of care will come into effect since early 2018 in korea. the investigators aim to determine 1) long-term neurological outcomes in patients who developed ihca, 2) whether early neurological status can predict late neurological status after ihca, and 3) whether the proportion of ihca survivors with good neurological outcomes will change since implementation of new legislation on withdrawal of care.

\ * day 0: neurological examination (first examination will be performed within 2 hours after ihca) * day1 - 7: neurological examination * day7, 14, 21, 28: neurological examination, cpc score * day90: cpc score, survival * day180: cpc score, survival * day 360: cpc score, survival \ * cpc 1: good cerebral performance * cpc 2: moderate cerebral disability(available for independent activities) * cpc 3: severe cerebral disability(dependent on others for daily support) * cpc 4: coma or vegetative state * cpc 5: brain death or death \ * acdu(alert/confused/drowsy/unresponsive) score * four(full outline of unresponsiveness) score

Eligibility criteria:
inclusion criteria: * age ≥ 18 * in-hospital cardiac arrest * cardiopulmonary resuscitation(cpr) code activation and/or neurology consultation for ihca exclusion criteria: * neither (cpr) code activation nor neurology consultation * development of ihca during transition period

Keywords: cardiac arrest inhospital cardiac arrest cardiopulmonary resuscitation
ed50 determination of hydroxyethylstarch for treatment of hypotension during cesarean section under spinal anesthesia

Conditions: Obstetric Anesthesia; Spinal Anesthesia; Hypotension; Fluid Therapy; Cesarean Section

Summary: the purpose of this trial is to determine the effective volume of hydroxyethylstarch 130/0.4 which would prevent the occurence of maternal hypotension in 50% of healthy pregnant women undergoing a cesarean section under spinal anesthesia.

the incidence of spinal anesthesia-induced hypotension in pregnant women undergoing a cesarean section is high. a preoperative fluid bolus of undetermined volume is frequently administered to lower the incidence of maternal hypotension, with a somewhat poor efficacy. recently, several investigations have shown that the use of a phenylephrine infusion after the induction of spinal anesthesia results in a significant reduction in hypotensive episodes. given the high efficacy of this therapy (incidence of hypotension around 20%), it is possible to determine the effective volume of fluid which would prevent hypotension in 50% of the patients studied (ed50). healthy term pregnant women undergoing elective cesarean section under spinal anesthesia will be recruited in this trial. the spinal anesthesia regimen will be standardized and all subjects will receive a phenylephrine infusion. the fluid investigated is hydroxyethylstarch (hes) 130/0.4 (volulyte(r)). the ed50 will be determined using an up-down sequential allocation method initially described by dixon \& massey. the determination of the hes ed50 will help the anesthesiologist in further treating maternal hypotension appropriately.

Eligibility criteria:
inclusion criteria: * healthy pregnant women (asa i or ii) * normal pregnancy * term gestation (37 weeks and above) * elective cesarean section * spinal anesthesia exclusion criteria: * cardiopathies * hypertensive disease/ pre-eclampsia / eclampsia * any contraindication to neuraxial anesthesia * patient refusal * body mass index \> 30 at first antenatal visit and \> 32 at cesarean section * twin pregnancy * known allergies to hes * emergency cesarean section

Keywords: obstetric anesthesia spinal anesthesia hypotension fluid therapy cesarean section phenylephrine cardiac output
pilot for the precision exercise regimen for cancer care (percc) study

Conditions: NSCLC Stage II; NSCLC, Stage III

Summary: this study is designed to evaluate whether a precision exercise regimen is feasible to implement within cancer populations, specifically stage ii-iii primary lung cancer patients receiving multimodal therapy, and delivered through telehealth.

this is a pilot study evaluating the feasibility of the precision exercise regimen for cancer care (percc) intervention in stage ii and stage iii non-small cell lung cancer (nsclc) patients receiving multimodal therapy at the huntsman cancer institute (hci) at the university of utah. eligible patients will begin the intervention at the pre-treatment clinic visit and continue until approximately two months post-surgery. the percc intervention is a virtually supervised home-based exercise program. participants will engage in exercise starting at least two weeks before receiving their first neoadjuvant treatment for lung cancer and continuing until two months after receiving surgical treatment. the exercise modes will include basic transfer and calisthenics mobility, aerobic, and resistance exercises and will be performed in various postures (supine, sitting, standing, and walking) with variable challenges (level walking, bending, inclines, steps, and squatting).

Eligibility criteria:
inclusion criteria: * ages 18 and older at time of diagnosis * patient diagnosed with stage ii and iii non-small cell lung cancer (nsclc) * patient receives either neoadjuvant chemotherapy or immunotherapy and surgery * patient able to follow direction and complete questionnaires in english or spanish * patient agrees to complete the percc intervention exclusion criteria: * morbidly obese (bmi \>40 kg/m2 ) or anorexic (bmi \<17.5 kg/m2 ) * abnormalities on screening physical exam per study physicians or physical therapist to contraindicate participation in exercise program compliance * alcohol or drug abuse, significant mental or emotional problems that would interfere with compliance (assessed by nccn distress thermometer) * patient scheduled to receive single modality cancer treatment (unimodal therapy), scheduled to begin treatment within 2 weeks of the pre-treatment clinic visit, or for whom treatment has already started
study of nimotuzumab to treat esophageal squamous cell carcinoma.

Conditions: Esophageal Squamous Cell Cancer

Summary: nimotuzumab is an igg1 humanized monoclonal antibody that recognized an epitope located in the extra cellular domain of the human epidermal growth factor receptor (egfr). clinical efficacy has been shown in adult with head and neck cancer. the study assessed the safety and efficacy of different dosage of nimotuzumab in second or late- line treatment of patients with locally advanced or metastatic esophageal squamous cell carcinomas.


Eligibility criteria:
inclusion criteria: * histologically confirmed esophageal squamous carcinoma,failed to first or second line chemothrepay * age 18 to 75 years old * measurable disease according to the recist criteria(diameter of the lesion should be more than 10mm by spiral ct or mri, more than 20mm by common ct, the date of image should be less than 15 days before enrollment) * life expectancy of ≥3 month * karnofsky performance status ≥80 * wbc\>3,000/mm3, absolute neutrophil count ≥1500/mm3, platelet\>100,000/mm3, hb\>9g/dl，bilirubin level \< 1.0 times uln，serum creatinine \<1.0 times uln，alt and ast\<2.5 times uln ，akp \< 2.5 times uln ，(≤5 times uln in patients with liver metastases)(within 7 days before enrollment) * no sever complication, such as active gastrointestinal bleeding, perforation, jaundice, obstruction, non-cancerous fever\>38℃； * normal ecg/cardiac function * good compliance * having signed informed consent - exclusion criteria: * no previous systemic therapy for metastatic esophageal squamous carcinoma * known hypersensitivity to study drugs * tumor with length≥10cm, liver metastasis covers more than 50% of liver,or lung metastasis covers more than 25% of lung * no measurable lesions, eg. pleural fluid and ascites * only with other previous malignancy within 5 year, except non-melanoma skin cancer * heart failure or other sever organ dysfunction, eg. coronary artery disease, myocardial infarction within the last 6 months only brain or bone metastasis * chronic diarrhea * mentally abnormal or disable cognition,including cns metastasis * pregnancy or lactation period
apixaban for the prevention of stroke in subjects with atrial fibrillation

Conditions: Atrial Fibrillation; Atrial Flutter

Summary: the trial seeks to determine if apixaban, an investigational anticoagulant (blood-thinner) is as effective as standard therapy (warfarin) in preventing stroke and systemic embolism in subjects with atrial fibrillation and risk factors for stroke.


Eligibility criteria:
inclusion criteria: * males and females ≥ 18 yrs with atrial fibrillation (af) and one or more of the following risk factors for stroke: * age ≥ 75, previous stroke * transient ischemic attack (tia) or systemic embolism (se) * symptomatic congestive heart failure or left ventricular dysfunction with left ventricular ejection fraction (lvef) ≤ 40% * diabetes mellitus or hypertension requiring pharmacological treatment
learning skills together family caregiver complex intervention

Conditions: Dementia; Alzheimer Disease; Caregiver Burden; Self Efficacy

Summary: learning skills together (lst) is a 6-week psychoeducational intervention focused on complex care (nursing) tasks completed by family caregivers to persons living with alzheimer's disease and related dementias. this study aims to test the efficacy of lst at reducing caregiver depression and negative appraisal of behavioral symptoms of dementia by building caregiver self-efficacy. to do this, eligible participants will be randomized into an intervention group (lst) or a control group condition focused on healthy living for family caregivers. participants will be asked to complete surveys before and after participating in the intervention or the control condition to determine whether change in hypothesized outcomes can be attributed to the intervention condition.


Eligibility criteria:
inclusion criteria: * is aged 18 years or older * be a family member, including "families of choice," to an individual living with alzheimer's disease or a related dementia who has received a diagnosis from a physician * provide assistance with at least two instrumental activities of daily living or one activity of daily living * report a global deterioration scale (gds) rating for care recipients between 4 to 6 * commit to attending at least 5 of the 6 discussion sessions * has reliable access to the internet and email and be able to attend synchronous sessions using the zoom videoconferencing platform exclusion criteria: * unable to read and speak english * participated in learning skills together in the past * plans to place the care recipient in a skilled nursing facility within the next 9 months (i.e., study duration) * was diagnosed with depression and/or started or significantly altered their depression treatment, including starting a pharmacological therapy or beginning therapy, in the previous 3 months
evaluation of efficacy and safety of tralokinumab in patients with active, moderate-to-severe ulcerative colitis

Conditions: Ulcerative Colitis

Summary: the study is designed to evaluate the clinical efficacy and safety of tralokinumab as compared to placebo. investigational product will be administered as subcutaneous injection. all patients will continue background therapy for ulcerative colitis as per local standards of care in addition to investigational product.

a phase iia, randomised, double-blind, placebo-controlled, parallel-arm, multicenter study to evaluate the efficacy and safety of tralokinumab (cat-354), a recombinant human monoclonal antibody directed against interleukin-13 (il-13), as add-on therapy, on clinical response in patients with active, moderate-to-severe, ulcerative colitis

Eligibility criteria:
inclusion criteria: * diagnosed ulcerative colitis at least 90 days prior randomisation. * men or women age 18 - 75 years. * non-hospitalized patients with moderate-severe ulcerative colitis treated with stable background uc therapy (e.g. containing 5-aminosalicylates, and/or low dose of glucocorticosteroids, and/or purine analogue) prior to randomization. * females of childbearing potential who are sexually active with a nonsterilized male partner must use highly effective contraception from day1. * nonsterilized males or sterilized males who are ≤1 year post-vasectomy who are sexually active with a female partner of childbearing potential must use a highly effective method of contraception. exclusion criteria: * pregnant or breastfeeding women. * history of colostomy. * current diagnosis of indeterminate colitis, crohn's disease, ischemic colitis, fulminant colitis and/or toxic megacolon and patients with ulcerative colitis limited to the rectum (ulcerative proctitis). * hepatitis b, c or hiv. * history of cancer.

Keywords: tralokinumab inflammatory bowel disease moderate to severe ulcerative colitis
ibrutinib in relapsed nodular lymphocyte-predominant hodgkin lymphoma (nlphl)

Conditions: Nodular Lymphocyte-Predominant Hodgkin's Lymphoma

Summary: the purpose of this trial is to determine 1. disease stabilization/response rate after six 21-day cycles of ibrutinib 2. remission status after six, twelve and 20 21-day cycles of ibrutinib


Eligibility criteria:
inclusion criteria (key criteria): 1. histologically proven relapsed nodular lymphocyte-predominant hodgkin lymphoma (nlphl) as confirmed by expert review 2. age at entry 18-99 years 3. ecog status 0-2 4. absolute leukocyte count \> 2.500/mm3 5. absolute neutrophil count \> 1.000/mm3 independent of growth factor support 6. platelet count \> 100.000/mm3 or \> 50.000/mm3 in case of bone marrow involvement independent of transfusion support in either situation 7. gpt and got ≤ 3 x upper limit of normal (uln) exclusion criteria (key criteria): 1. classical hl (chl) or composite lymphoma 2. known central nervous lymphoma 3. prior btk inhibitor treatment 4. life expectancy \< 3 months 5. major surgery within 4 weeks of study inclusion 6. history of stroke or intracranial hemorrhage within 6 months prior to the first study drug 7. current anticoagulation with warfarin or equivalent vitamin k antagonists
exercise pulseoximetry for pre-flight evaluation of chronic obstructive pulmonary disease (copd) patients

Conditions: Chronic Obstructive Pulmonary Disease; Hypoxemia

Summary: some patients with chronic obstructive pulmonary disease (copd) need supplementary oxygen during air travel. guidelines issued by the british thoracic society (bts) for pre-flight evaluation do not discriminate sufficiently between those who need supplementary oxygen during flight, and those who can do without. previous studies have indicated that decreasing hemoglobin oxygen saturation during exercise may predict in-flight hypoxemia. the objective of the present study is to examine if adding exercise oxygen desaturation to the bts algorithm will better predict requirements for in-flight supplementary oxygen.

the british thoracic society (bts) guidelines on pre-flight evaluation for patients with chronic respiratory disease is based on an algorithm where arterial oxygen saturation is the discriminating factor. it has recently been shown that this algorithm does not discriminate sufficiently between patients who need pre-flight evaluation and maybe supplementary oxygen during air travel, and those who can travel by air without supplemental oxygen or further evaluation. studies have also shown that exercise desaturation may predict in-flight hypoxemia. the objective of the present study is to examine if inclusion of arterial oxygen saturation measured by pulseoximetry during exercise in the bts algorithm, will increase the sensitivity and specificity of the bts pre-flight evaluation guidelines.the study also include questionnaires on symptoms during air travel carried out before ande after the pre-flight evaluation.

Eligibility criteria:
inclusion criteria: * patients with copd who have performed a hypoxia altitude simulation test * able to perform the 6-minute walking test exclusion criteria: * unstable angina * uncontrolled hypertension * uncontrolled arrythmia * patients with long-term oxygen treatment

Keywords: chronic obstructive pulmonary disease hypoxemia pre-flight evaluation hypobaria copd pulseoximetry air travel exercise desaturation
a new marker for early diagnosis of pneumoperitoneum-related acute kidney injury: insulin-like growth factor-1 (igf-1)

Conditions: Acute Kidney Injury (Nontraumatic); Pneumoperitoneum

Summary: in our study, to show the effect of pneumoperitoneum on acute kidney injury in patients scheduled for laparoscopic surgery, ngal and igf-1 values will be measured before, after and 24 hours after pneumoperitoneum, and these values will be compared. in our study, we aimed to investigate the effect of pneumoperitoneum applied on acute kidney injury in patients who underwent laparoscopic surgery. creatinine and ngal have been used successfully in the follow-up of acute kidney injury. our study investigates whether igf-1 will be an effective indicator in acute kidney injury by comparing igf-1 and ngal values before pneumoperitoneum, after pneumoperitoneum and at the postoperative 24th hour.


Eligibility criteria:
inclusion criteria: * patients aged 18-70 years of both sexes * asa i-iii patients exclusion criteria: * obesity, * chronic kidney disease, * chronic renal failure, * acute renal failure, * peripheral and ischemic vascular disease, * chronic heart failure, * history of anaphylaxis, * a-v block, * creatinine level \>1.4, * neuromuscular disease, * malignant hypertension, * pyelonephritis, * urinary tract infectio, * severe inflammation/possible sepsis, * active malignancy, * patients with surgery reversion to laparotomy, * hemodynamic instability, need for vasopressors, * severe bleeding requiring blood transfusion,
lifestyle, adiposity and cardiovascular health in youths

Conditions: Cardiovascular Diseases; Heart Diseases; Obesity

Summary: to determine the influences of diet and physical activity (pa) on total body fatness and regional fat distribution and the relationship of these to risk factors of cardiovascular disease during adolescence.

background: adult studies have shown that adiposity, especially visceral adipose tissue, and cardiovascular (cv) fitness are key links between lifestyle factors like diet and exercise on one hand, and cv disease on the other. however, very little is known about these links during the juvenile years, when the processes leading to cv disease are at an early stage of development. the study is in response to a program announcement issued in march 1998 on diet and cardiovascular disease risk in children and adolescents. the program announcement, jointly issued by the national institute of nursing research and the nhlbi, sought to encourage research relevant to the development and/or testing of dietary interventions to improve the cardiovascular disease (cvd) risk profiles in children and adolescents, especially those at increased risk for cvd or for development of cvd risk factors because of genetics, family history, socioeconomic status (ses), race/ethnicity, levels of blood cholesterol or blood pressure, or other factors. design narrative: the study determines the relations of free-living diet and exercise to total body percent fat ( percent bf), visceral adipose tissue and cv fitness in black and white boys and girls of varying socioeconomic status (ses). the study also determines the relations of fatness and fitness to different cvd risk factors. a total of 800 15 to 18 year olds, 200 in each ethnic and gender subgroup will be recruited. diet will be assessed with seven 24-hour recalls, and exercise with two seven-day recalls and heart rate monitoring. percent body fat will be measured with dual-energy x-ray absorptiometry, visceral adipose tissue with magnetic resonance imaging and cv fitness with a multi-stage treadmill test. measurements will be made of major fatness- and fitness-related cv disease risk factors (e.g., total cholesterol:hdl cholesterol ratio, insulin, systolic blood pressure, left ventricular mass indexed to height, fibrinogen). multivariate and univariate analyses will be conducted to determine relationships.

Eligibility criteria:
no eligibility criteria
comparison of prophylactic antiviral efficacy in patients undergoing chemotherapy: entecavir versus lamivudine

Conditions: Malignancy; Hepatitis B

Summary: patients with chronic hepatitis b who are undergoing anticancer chemotherapy are at risk of hbv reactivation and hepatitis flare. lamivudine (lam) prophylaxis has been recommended in such circumstance according to the practice guidelines despite of limited evidence. however, failure of lam prophylaxis including virologic breakthrough and withdrawal hepatitis occurs occasionally, which may lead to liver-related morbidity and mortality as well as premature interruption or a delay of chemotherapy. given relatively frequent drug resistance of lam, studies on the proper prophylactic antiviral regimen is warranted. the present multicenter, prospective, randomized study aims to compare the effect of entecavir (etv) versus lam for the prevention of hbv reactivation in hbsag-positive patients with hematologic and oncologic malignancy undergoing cytotoxic chemotherapy.

chronic hepatitis b virus (hbv) carriers who are undergoing anticancer chemotherapy are at risk of hbv reactivation and hepatitis flare, and lamivudine (lam) prophylaxis is recommended according to the practice guidelines despite of limited evidence. however, failure of lam prophylaxis defined as virologic breakthrough during lam therapy and withdrawal hepatitis after discontinuation of lam therapy occurs occasionally, which may lead to liver-related morbidity and mortality as well as premature interruption or a delay of chemotherapy. considering that lam therapy showed relatively higher rates of drug resistance and of withdrawal hepatitis, studies on the better choice of prophylactic antiviral regimen is warranted. the purpose of our study is to conduct a multicenter, prospective, randomized study comparing the effect of entecavir (etv) versus lam for the prevention of hbv reactivation in hbsag-positive patients with hematologic and oncologic malignancy undergoing cytotoxic chemotherapy. a total one hundred eighty hbv carriers with malignancy undergoing chemotherapy will be randomly assigned to each prophylactic therapy arm of etv and lam group. the primary endpoint of the study is the hbv reactivation rate during antiviral therapy and 6 months after discontinuation of prophylactic antiviral therapy. if the prophylactic efficacy of etv is superior to that of lam, etv will be the preferred prophylactic therapy for hbsag-positive cancer patients undergoing chemotherapy.

Eligibility criteria:
inclusion criteria: * 18 years or older * positive for hbsag for at least 6 months * inactive or active carrier of hbv with alt level \<2xuln, chronic hepatitis and compensated cirrhosis (child-pugh class a) * malignant tumors: non-hodgkin's lymphoma undergoing systemic chemotherapy; solid tumors undergoing chemotherapy (including adjuvant/neoadjuvant chemotherapy or concurrent chemoradiation therapy) exclusion criteria: * positive for anti-hcv or anti-hiv antibodies * decompensated cirrhosis or hepatocellular carcinoma * expected survival of less than 1 year

Keywords: malignancy hepatitis b lamivudine entecavir prophylaxis